McKesson Corp. Stock
McKesson Corp. Stock
We can see a decrease in the price for McKesson Corp.. Compared to yesterday it has lost -€6.400 (-1.270%).
With 16 Buy predictions and not the single Sell prediction the community is currently very high on McKesson Corp..
With a target price of 523 € there is a slightly positive potential of 5.78% for McKesson Corp. compared to the current price of 494.4 €.
Pros and Cons of McKesson Corp. in the next few years
Pros
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of McKesson Corp. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
McKesson Corp. | -1.270% | -1.749% | -0.222% | 50.274% | 19.420% | 216.923% | 363.529% |
Cardinal Health Inc. | 1.490% | -0.785% | -7.047% | 28.266% | 6.689% | 91.351% | 122.733% |
CVS Health Corp. | -19.000% | -18.069% | -25.000% | -22.185% | -28.224% | -19.100% | 1.580% |
AmerisourceBergen Corp. | -6.210% | -6.240% | -7.174% | 35.611% | 13.938% | 107.525% | 213.913% |
Comments
McKesson Co. (NYSE: MCK) had its price target raised by analysts at Citigroup Inc. from $575.00 to $620.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MCK provided by MarketBeat
McKesson Co. (NYSE: MCK) had its price target raised by analysts at Morgan Stanley from $522.00 to $548.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for MCK provided by MarketBeat
McKesson Co. (NYSE: MCK) had its price target raised by analysts at Argus from $510.00 to $570.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MCK provided by MarketBeat
News
McKesson (MCK) Q3 2024 Earnings Call Transcript
This 1 Surprising New Tailwind Is Lifting These 2 Evergreen Stocks
Bigtime medical distributors like McKesson (NYSE: MCK) and Cencora (NYSE: COR) make money by moving drugs and supplies to clinics and pharmacies worldwide. While investors usually look to such